Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice

BACKGROUND: Oral cholinesterase inhibitors at doses efficacious for the treatment of Alzheimer’s disease (AD) are often prematurely discontinued due to gastrointestinal side effects. In controlled clinical trials, transdermal rivastigmine demonstrated less such effects at similar efficacy. The curre...

Descripción completa

Detalles Bibliográficos
Autores principales: Seibert, Johannes, Tracik, Ferenc, Articus, Konstantin, Spittler, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333784/
https://www.ncbi.nlm.nih.gov/pubmed/22536070
http://dx.doi.org/10.2147/NDT.S29116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333784/
https://www.ncbi.nlm.nih.gov/pubmed/22536070
http://dx.doi.org/10.2147/NDT.S29116

Ejemplares similares